A/Prof David Anderson
Deputy Director
Centre for Biomedical Research
Burnet Institute
anderson@burnet.edu.au
Licensing opportunities
Burnet spinoff Nanjing BioPoint Diagnostics is interested in novel diagnostics for unmet medical needs especially using lateral flow immunochromatography, with R&D both at Burnet and in Nanjing to help convert promising assays from other formats such as ELISAsISAs
EMAIL ENQUIRY >
Contract research opportunities
Development of point of care (lateral flow) diagnosticstics
EMAIL ENQUIRY >
Research Activities
Our major activities are in translational research in diagnostics:(1) the development of rapid, point-of-care and/or laboratory-based assays for the diagnosis and management of infectious diseases including HIV, syphilis, hepatitis and liver disease, gut leakage and sepsis;
(2) commercial development of diagnostics through Burnet's spinoff company, Nanjing BioPoint Diagnostics (PR China), with ISO13485 (2016) certified manufacturing facilities in China, allowing production for registration and sale (eg CE mark for EU and other markets).
Techniques/Expertise
Assay development, validation and pilot manufacture for ELISA and rapid, point of care tests (including contract services)Collaborations
Suzanne CroweBrendan Crabb
Greg Tannock, Burnet Institute
Alan Landay, Rush University, Chicago
Tom Denny, Duke University, Durham
Bill Heath, Axxin Ltd
A/Prof Rosemary Ffrench
Jack Richards
Mary Garcia
Roy Hall
Jody Peters
Other Lab Members
Mary GarciaHuy Van
Fan Li
Research Images
